-

KORU Medical Systems to Participate in Upcoming Investor Conferences

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will be participating in two upcoming Investor Conferences.

KORU Medical’s management team is participating at the 15th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 19th, 2024.

KORU Medical’s management team will also be participating at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 21st, 2024.

About KORU Medical Systems

KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

Contacts

Investor Contact:
Louisa Smith
investor@korumedical.com

Industry:

KORU Medical Systems

NASDAQ:KRMD
Release Versions
English

Contacts

Investor Contact:
Louisa Smith
investor@korumedical.com

More News From KORU Medical Systems

KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9...

KORU Medical Systems Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced inducement equity awards to Eric Schiller, Chief Technology Officer, pursuant to his previously announced employment agreement with the Company dated as of December 11, 2025. Mr. Schiller was g...

KORU Medical Systems Announces 510(k) Submission for Clearance of the FreedomEDGE® System with a Commercialized Oncology Biologic

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) seeking clearance for the use of KORU Medical’s FreedomEDGE® infusion system to subcutaneously a...
Back to Newsroom